Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine and NewYork-Presbyterian Hospital, 525 E 68thSt. F20, New York, NY, 10065, USA.
Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.
Obes Res Clin Pract. 2021 Jan-Feb;15(1):64-68. doi: 10.1016/j.orcp.2020.12.005. Epub 2020 Dec 30.
It is unknown whether weight loss outcomes differ with metformin monotherapy in patients with obesity with or without type 2 diabetes (T2DM)/prediabetes (PreDM). In this retrospective study, 6- or 12-month weight loss outcomes were compared in 222 patients with or without T2DM/preDM who completed metformin monotherapy. Average weight loss was similar between groups, euglycemic vs. T2DM/preDM (6 months: 6.5 [6.0%] vs. 6.5 [6.1%] p = 0.97; 12 months: 7.4 [6.2%] vs. 7.3 [7.7%], p = 0.92). Categorical weight losses (≥5% and ≥10% of baseline weight) were also similar. Comparable clinically significant weight loss was achieved with metformin monotherapy in patients with obesity with or without T2DM/PreDM.
尚不清楚在肥胖伴或不伴 2 型糖尿病（T2DM）/糖尿病前期（PreDM）的患者中，二甲双胍单药治疗的减肥效果是否存在差异。在这项回顾性研究中，比较了 222 例完成二甲双胍单药治疗的伴或不伴 T2DM/PreDM 的患者的 6 个月或 12 个月的减肥效果。两组之间的平均体重减轻相似，血糖正常组与 T2DM/PreDM 组相比（6 个月：6.5[6.0%] vs. 6.5[6.1%]，p=0.97；12 个月：7.4[6.2%] vs. 7.3[7.7%]，p=0.92）。体重减轻的分类（基线体重的≥5%和≥10%）也相似。在肥胖伴或不伴 T2DM/PreDM 的患者中，使用二甲双胍单药治疗可实现相当的临床显著体重减轻。
